Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus

Lupus

Volumn 19, Issue 8, 2010, Pages 927-934

  Ferreira, G A ^a   Teixeira, A L ^a   Sato, E I ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

atorvastatin; chemokine; systemic lupus erythematosus

Indexed keywords

ATORVASTATIN; CXCL9 CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISONE; CHEMOKINE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; PYRROLE DERIVATIVE;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; UNIVARIATE ANALYSIS; BLOOD; CLINICAL TRIAL; DISEASE COURSE; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

ADULT; CHEMOKINE CXCL9; CHEMOKINES; DISEASE PROGRESSION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERONS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PYRROLES; SEVERITY OF ILLNESS INDEX;

EID: 77954043920     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310364400     Document Type: Article

References (31)

1. Baggiolino M. Chemokines and leukocyte traffic. Nature 1998 ; 392: 565-568.
2. Eriksson C., Eneslätt K., Ivanoff J., Rantapää-Dahlqvist S., Sundqvist K-G. Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus. Lupus 2003 ; 12: 766-774.
3. Robinson E., Keystone EC, Schall TJ, Gillett N., Fish EN Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1α production by synovial T Cells. Clin Exp Immunol 1995 ; 101: 398-407.
4. Hasegawa M., Sato S., Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β) in patients with systemic sclerosis: MCP-1 and MIP-1á may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999 ; 117: 159-165.
5. Vilá LM, Molina MJ, Mayor AM, Cruz JJ, Rios-Olivares E., Rios Z. Association of serum MIP-1 alpha, MIP-1 beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin Rheumatol 2007 ; 26: 718-722.
6. Bauer JW, Baechler EC, Petri M., et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006 ; 3: e491.
7. Lit LCW, Wong CK, Tam LS, Li EKM, Lam CW Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2006 ; 65: 209-215.
8. Fu Q., Chen X., Cui H., et al. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther 2008 ; 10: R112.
9. Noris M., Bernasconi S., Casiraghi F., et al. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995 ; 73: 804-809.
10. Wada T., Yokoyama H., Su SB, et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996 ; 49: 761-767.
11. Meller S., Winterberg F., Gilliet M., et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005 ; 52: 1504-1516.
12. Wenzel J., Worenkamper E., Freutel S., et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005 ; 205: 435-442.
13. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004 ; 109: 39-43.
14. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000 ; 6: 1399-1402.
15. Mason JC Statins and their role in vascular protection. Clin Sci 2003 ; 105: 251-266.
16. Ascer E., Bertolami MC, Venturinelli ML, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004 ; 177: 161-166.
17. Meroni PL, Luzzana C., Ventura D. Anti-inflammatory and immunomodulating properties of statins An additional tool for the therapeutic approach of systemic autoimmune disease?. Clin Rev Allerg Immunol 2002 ; 23: 263-277.
18. Leung BP, Sattar N., Crilly A., et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003 ; 170: 1524-1530.
19. Ferreira GA, Navarro TP, Telles RW, Andrade LEC, Sato EI Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology 2007 ; 46: 1560-1565.
20. Hochberg MG Update the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997 ; 40: 1725.
21. Bombardier C., Gladman DD, Urowitz MB, Caron D., Chang CH Derivation of the SLEDAI: a disease activity index for lupus patients: the committee on Prognosis Studies in SLE. Arthritis Rheum 1992 ; 35: 630-640.
22. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997 ; 40: 809-813.
23. Anger T., Pohle FK, Kandler L., et al. VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: effects of statins. Exp Mol Pathol 2007 ; 83: 435-442.
24. Mach F., Sauty A., Iarossi AS, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999 ; 104: 1041-1050.
25. Sheikh AM, Ochi H., Manabe A., Masuda J. Lysophosphatidylcholine posttranscriptionally inhibits interferon-gamma-induced IP-10, Mig and ITac expression in endothelial cells. Cardiovasc Res 2005 ; 65: 263-271.
26. Moore KJ, Wada T., Barbee SD, Kelley VR Gene transfer of RANTES elicits autoimmune renal injury in MRL-Fas(1pr) mice. Kidney Int 1998 ; 53: 1631-1641.
27. Stahl RA, Thaiss F., Disser M., Helmchen U., Hora K., Schlondorff D. Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int 1993 ; 44: 1036-1047.
28. Chan RW, Tam LS, Li EK, et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2003 ; 48: 1326-1331.
29. Enghard P., Humrich JY, Rudolph B., et al. CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum 2009 ; 60: 199-206.
30. Yajima N., Kasama T., Isozaki T., et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum 2005 ; 52: 1670-1675.
31. Grip O., Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's Disease. PLoS ONE 2009 ; 4: e5263.